Lipum AB (publ) has terminated the liquidity provider assignment with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB as new liquidity provider for the company's shares on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm's rules on liquidity providers.

In the role of liquidity provider Carnegie undertakes to continuously quote prices for the "Lipum" share in accordance with the from time-to-time applicable minimum requirements for liquidity providers set out by Nasdaq Stockholm. The purpose is to improve the liquidity of the share and reduce the spread between the buying and selling price.
 
Carnegie's assignment commences on 30 November 2023.

Contacts
Einar Pontén, CEO
einar.ponten@lipum.se
+46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum changes its liquidity provider to Carnegie Investment Bank AB

Lipum changes its liquidity provider to Carnegie Investment Bank AB